Uses
UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1].
in vivo
UC2888 (oral gavage; 15 mg/kg; 3 times a week; 4 weeks) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[2].UC2288 (intraperitoneal injection; 10 mg/kg; 4 times in 7 days) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[3].
| Animal Model: | Eight-week old, athymic nude (NCr nu/nu) mice injected subcutaneously with HCT116 and ACHN cancer cells(2.5x106)[2] |
| Dosage: | 15 mg/kg |
| Administration: | Oral gavage; 3 times a week; 4 weeks; co-treatment with imetelstat |
| Result: | Combined treatment with imetelstat synergistically inhibited tumor growth in mice. |
| Animal Model: | MPTP-induced C57BL6 Parkinson’s disease mice model[3] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitonealinjection; 4 times in 7 days |
| Result: | Ameliorated MPTP induced PD progression through inhibition of neuroinammation. |
References
[1] Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther.2013 Mar;14(3):278-85. DOI:
10.4161/cbt.23374[2] Romi Gupta, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71. DOI:
10.1073/pnas.1411370111[3] Jun Hyung Im, et al. p21 inhibitor UC2288 ameliorates MPTP induced Parkinson’s disease progression through inhibition of oxidative stress and neuroinammation. Translational Medicine.Neurobiology of Disease